| 本文已被：浏览 69次 下载 56次 |
码上扫一扫！ |
| 祛风宁肺散抑制儿童咳嗽变异性哮喘急性发作期气道炎症的临床研究 |
| 赵欣1,2,袁世帅1,2,肖婧雯1,肖和印1,郭凯1,董国伟1,张瑞航1,陈艳霞1 |
| (1. 中国中医科学院望京医院,北京 100102;2. 北京中医药大学,北京 100029) |
|
| 摘要: |
| 目的:评价祛风宁肺散对儿童咳嗽变异性哮喘(CVA)急性发作期的咳嗽症状及临床指标的改善情况。 方法:采用前瞻 性、随机、对照研究设计,试验组给予祛风宁肺散治疗,对照组给予孟鲁司特钠咀嚼片治疗,疗程 28 d。 通过治疗前后咳嗽的改 善情况、中医证候分级量化表的变化情况和相关理化检查指标,评价祛风宁肺散的临床疗效和安全性。 结果:共纳入 100 例受 试者,试验中剔除 1 例,脱落 4 例,最终纳入试验组 48 例,对照组 47 例。 结果表明,两组用药前咳嗽积分、临床指标(如血清 IL-6、 TNF-α、IgE 水平和 FeNO)比较差异无统计学意义(P>0. 05),用药后均下降,且试验组的日间和夜间咳嗽积分均低于对照组(均 P<0. 01)。 结论:祛风宁肺散能有效抑制 CVA 患儿急性发作期气道炎症,且安全性良好。 |
| 关键词: 咳嗽变异性哮喘 气道炎症 祛风宁肺散 儿童 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2026.09.006 |
|
| 基金项目:中国中医科学院科技创新工程重大攻关项目,编号 CI2021A02507;北京市科委首都临床特色应用研究与成果推广项目,编号 Z171100001017109。 |
|
| Clinical Study on Inhibition of Airway Inflammation During Acute Exacerbation Period in Children with Cough Variant Asthma by Qufeng Ningfei Powder |
| Zhao Xin1,2, Yuan Shishuai1,2, Xiao Jingwen1, Xiao Heyin1, Guo Kai1, Dong Guowei1, Zhang Ruihang1, Chen Yanxia1 |
| (1. Wang Jing Hospital of CACMS, Beijing 100102, China; 2. Beijing University of Chinese Medicine, Beijing 100029, China) |
| Abstract: |
| Objective: To evaluate the improvement of cough symptoms and clinical indicators in children with acute exacerbation of cough variant asthma (CVA) treated with Qufeng Ningfei powder. Methods: A prospective, randomized, controlled study design was adopted. The experimental group received Qufeng Ningfei powder, while the control group was given montelukast sodium chewable tablets, with a treatment duration of 28 d. The clinical efficacy and safety of Qufeng Ningfei powder were assessed based on improvements in cough symptoms, changes in the Traditional Chinese Medicine syndrome grading quantification scale, and relevant physicochemical examination indicators before and after treatment. Results: A total of 100 subjects were enrolled, 1 case was excluded during the trial, and 4 subjects dropped out. Eventually, 48 subjects were included in the experimental group and 47 subjects in the control group. Results showed that there was no statistically significant difference in the cough scores and clinical indicators (serum IL-6, TNF-α, IgE and FeNO) between two groups before administration (P>0. 05). After administration, both groups exhibited significant reductions, with the experimental group showing lower daytime and nighttime cough scores compared with the control group (P<0. 01). Conclusion: Qufeng Ningfei powder could effectively inhibit airway inflammation in children with CVA during acute exacerbation period with higher safety. |
| Key words: cough variant asthma airway inflammation Qufeng Ningfei powder children |
